Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer



Status:Completed
Conditions:Cancer, Endocrine
Therapuetic Areas:Endocrinology, Oncology
Healthy:No
Age Range:18 - Any
Updated:9/15/2018
Start Date:October 15, 2009
End Date:August 30, 2017

Use our guide to learn which trials are right for you!

A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic
differentiated thyroid cancer refractory to radioiodine

Eligible subjects were randomized 1:1 to sorafenib 800 mg daily or matching placebo.
Progression was assessed every 8 weeks by modified RECIST criteria. Subjects had the option
to unblind study treatment after progression and to receive open label sorafenib regardless
of initial treatment assignment. Following discontinuation of study treatment, subjects were
followed for survival every 3 months in long-term follow-up. Subjects who terminated study
treatment (either double only or double blind and open label) for reasons other than death,
lost to follow-up or consent withdrawn entered long-term follow up

Inclusion Criteria:

- Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular
and Hurthle cell)

- Poorly differentiated and other thyroid variants (e.g. insular, tall cell, etc.) are
eligible provided that the histology has no medullary differentiation nor anaplastic
features

- Progression within 14 months (RECIST [Response Evaluation Criteria in Solid Tumors]
should be used as a basis for the assessment of disease progression)

- RAI (radioactive iodine) refractory

Exclusion Criteria:

- Histologic subtypes of thyroid cancer other than differentiated (i.e. like anaplastic
and medullary carcinoma, lymphoma or sarcoma)

- Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies
(licensed or investigational) that target VEGF (vascular endothelial growth factor) or
VEGF Receptors or other targeted agents

- Prior anti-cancer treatment for thyroid cancer with use of chemotherapy (low dose
chemotherapy for radiosensitization is allowed) or Thalidomide or any of its
derivatives
We found this trial at
14
sites
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Stanford, CA
Click here to add this to my saved trials
?
mi
from
Wien,
Click here to add this to my saved trials